19-Sep-2019: The global epigenetics
diagnostic market size is expected to reach USD 21.7
billion by 2026, expanding at a CAGR of 18.8% over the forecast period,
according to a new study by Grand View Research, Inc. Growing prevalence of
cancer and other diseases across the globe, along with epigenetic modification
base, is anticipated to fuel the industry growth during the forecast period.
Diagnostic
companies are upgrading their products by implementing new techniques for
attaining specific and sensitive results. Companies such as Abcam plc,
Invitrogen, and Sigma Aldrich Corporation are developing a new range of
Chromatin immunoprecipitation (ChIP)-validated antibodies specific for
detection of histone modifications at various loci.
In addition, many
biotechnology and pharmaceutical companies and academic research organizations
are collaborating to promote the growth of the epigenetics diagnostic industry.
Companies such as Epigenomics, OncoMethylome Sciences, and Orion Genomics have
collaborated with other laboratories and diagnostic companies that have
licensed their technology for development of Laboratory-developed Tests (LDTs).
Technological
advancements resulting in increased accuracy, portability, and
cost-effectiveness are expected to be a high-impact rendering driver in the
market. For instance, Diagenode has developed automated kits for detection and
purification of methylated DNA.
In
depth research report on Epigenetics Diagnostic Market
Further key findings from the study suggest:
·
On the basis of product, reagents held the largest share
owing to increasing R&D activities in field of epigenetics. Kits are
expected to witness high demand over the forecast period, expanding at a CAGR
of 19.2% due to need for rapid and accurate detection techniques
·
Based on technology, DNA methylation held a major share in
terms of revenue in 2018. Technological advancements such as Methylation
Sensitive PCR (MSP) and rapid adoption of these products to improve diagnostics
efficiency are the factors attributing to its largest share
·
Growing prevalence of cancer with epigenetic modification is
a key factor driving the oncology application segment. Solid tumors further
dominated the segment in 2018
·
North America emerged as a major regional market in 2018 due
to factors such as high levels of patient awareness, growing collaborations
between large pharmaceutical firms for development of improved therapeutics,
increasing funding for R&D, and increasing cancer prevalence
·
The market in Asia Pacific is estimated to witness
significant growth over the forecast period with a CAGR of 20.9% owing to the
presence of large target population having cancer, diabetes, and other chronic
disorders, along with parallel unmet clinical needs
·
Major players of the industry include Sigma-Aldrich
Corporation; Valirx Plc; Oncolys Biopharma Inc.; Zymo Research Corporation;
Qiagen; Thermo Fisher Scientific; Diagenode Diagnostics; and Illumina, Inc.
Extensive R&D initiatives for development of novel drugs and presence of
strong product pipeline are expected to further boost the market growth over
the forecast period.
Grand View Research
has segmented the global epigenetics diagnostic market on the basis of product,
technology, application, and region:
Epigenetics Diagnostic Product Outlook (Revenue, USD Million,
2014 - 2026)
·
Reagents
·
Kits
·
ChIP Sequencing Kit
·
Whole Genomic Amplification Kit
·
Bisulfite Conversion Kit
·
RNA Sequencing Kit
·
Others
·
Instruments
·
Enzymes
·
Services
Epigenetics Diagnostic Technology Outlook (Revenue, USD
Million, 2014 - 2026)
·
DNA Methylation
·
Reagents
·
Kits
·
Instruments
·
Enzymes
·
Services
·
Histone Methylation
·
Reagents
·
Kits
·
Instruments
·
Enzymes
·
Services
·
Histone Acetylation
·
Reagents
·
Kits
·
Instruments
·
Enzymes
·
Services
·
Large non-coding RNA
·
Reagents
·
Kits
·
Instruments
·
Enzymes
·
Services
·
MicroRNA modification
·
Reagents
·
Kits
·
Instruments
·
Enzymes
·
Services
·
Chromatin structures
·
Reagents
·
Kits
·
Instruments
·
Enzymes
·
Services
Epigenetics Diagnostic Application Outlook (Revenue, USD
Million, 2014 – 2026)
·
Oncology
·
Solid tumors
·
Liquid tumors
·
Non-oncology
·
Inflammatory diseases
·
Metabolic diseases
·
Infectious diseases
·
Cardiovascular diseases
·
Others
Browse
more research reports of this category:
About
Grand View Research
Grand View Research, Inc. is the
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides syndicated
research reports, customized research reports, and consulting services. To help
clients make informed business decisions, the company offers market
intelligence studies ensuring relevant and fact-based research across a range
of industries including technology, chemicals, materials, healthcare and
energy.
No comments:
Post a Comment